Cancer stem cells as a potential therapeutic target in thyroid carcinoma (Review)
- Authors:
- Luisa Vicari
- Cristina Colarossi
- Dario Giuffrida
- Ruggero De Maria
- Lorenzo Memeo
-
Affiliations: Cell Biology Unit, IOM Ricerca Srl, Viagrande I-95029 Catania, Italy, Department of Experimental Oncology, Mediterranean Institute of Oncology, Viagrande I‑95029 Catania, Italy, Regina Elena National Cancer Institute, I‑00144 Rome, Italy - Published online on: August 2, 2016 https://doi.org/10.3892/ol.2016.4936
- Pages: 2254-2260
This article is mentioned in:
Abstract
Viola D, Valerio L, Molinaro E, Agate L, Bottici V, Biagini A, Lorusso L, Cappagli V, Pieruzzi L, Giani C, et al: Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience. Endocr Relat Cancer. 23:R185–R205. 2016. View Article : Google Scholar : PubMed/NCBI | |
World Health Organization. WHO Classification of Tumours8. Pathology and Genetics of Tumours of Endocrine Organs. Third. IARC Press; Lyon: pp. 73–76. 2004 | |
Sherman SI: Thyroid carcinoma. Lancet. 361:501–511. 2003. View Article : Google Scholar : PubMed/NCBI | |
Nagaiah G, Hossain A, Mooney C, Parmentier J and Remick SC: Anaplastic thyroid cancer: A review of epidemiology, pathogenesis, and treatment. J Oncol. 2011:5423582011. View Article : Google Scholar : PubMed/NCBI | |
Perri F, Lorenzo GD, Scarpati GD and Buonerba C: Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options. World J Clin Oncol. 2:150–157. 2011. View Article : Google Scholar : PubMed/NCBI | |
Giuffrida D, Prestifilippo A, Scarfia A, Martino D and Marchisotta S: New treatment in advanced thyroid cancer. J Oncol. 2012:3916292012. View Article : Google Scholar : PubMed/NCBI | |
Jin S, Borkhuu O, Bao W and Yang YT: Signaling Pathways in thyroid cancer and their therapeutic implications. J Clin Med Res. 284–296. 2016. View Article : Google Scholar : PubMed/NCBI | |
Regalbuto C, Frasca F, Pellegriti G, Malandrino P, Marturano I, Di Carlo I and Pezzino V: Update on thyroid cancer treatment. Future Oncol. 8:1331–1348. 2012. View Article : Google Scholar : PubMed/NCBI | |
Podberezin M, Wen J and Chang CC: Cancer stem cells: A review of potential clinical applications. Arch Pathol Lab Med. 137:1111–1116. 2013. View Article : Google Scholar : PubMed/NCBI | |
Singh SR: Cancer stem cells: Recent developments and future prospects. Cancer Lett. 338:1–2. 2013. View Article : Google Scholar : PubMed/NCBI | |
O'Brien CA, Kreso A and Jamieson CH: Cancer stem cells and self-renewal. Clin Cancer Res. 16:3113–3120. 2010. View Article : Google Scholar : PubMed/NCBI | |
Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI | |
AlHaj JM, Wicha MS, BenitoHernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI | |
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB: Identification of human brain tumour initiating cells. Nature. 432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI | |
Collins AT, Berry PA, Hyde C, Stower MJ and Maitland N: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65:10946–10951. 2005. View Article : Google Scholar : PubMed/NCBI | |
RicciVitiani L, Fabrizi E, Palio E and De Maria R: Colon cancer stem cells. J Mol Med (Berl). 87:1097–1104. 2009. View Article : Google Scholar : PubMed/NCBI | |
RicciVitiani L, Pagliuca A, Palio E, Zeuner A and De Maria R: Colon cancer stem cells. Gut. 57:538–548. 2008. View Article : Google Scholar : PubMed/NCBI | |
RicciVitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C and De Maria R: Identification and expansion of human colon-cancer-initiating cells. Nature. 445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI | |
Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF and Ailles LE: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA. 104:973–978. 2007. View Article : Google Scholar : PubMed/NCBI | |
Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C and De Maria R: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15:504–514. 2008. View Article : Google Scholar : PubMed/NCBI | |
Schatton T and Frank MH: Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res. 21:39–55. 2008. View Article : Google Scholar : PubMed/NCBI | |
Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, Chu PW, Lam CT, Poon RT and Fan ST: Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell. 13:153–166. 2008. View Article : Google Scholar : PubMed/NCBI | |
Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, Roberts DJ, Seiden MV, Scadden DT, Rueda BR and Foster R: CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells. 27:2875–2883. 2009.PubMed/NCBI | |
Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identification of pancreatic cancer stem cells. Cancer Res. 67:1030–1037. 2007. View Article : Google Scholar : PubMed/NCBI | |
Lin RY: Thyroid cancer stem cells. Nat Rev Endocrinol. 7:609–616. 2011. View Article : Google Scholar : PubMed/NCBI | |
Maugeri-Saccà M, Vigneri P and De Maria R: Cancer stem cells and chemosensitivity. Clin Cancer Res. 17:4942–4927. 2011. View Article : Google Scholar : PubMed/NCBI | |
Giuffrida R, Adamo L, Iannolo G, Vicari L, Giuffrida D, Eramo A, Gulisano M, Memeo L and Conticello C: Resistance of papillary thyroid cancer stem cells to chemotherapy. Oncology Letters. 12:687–691. 2016.PubMed/NCBI | |
Nguyen LV, Vanner R, Dirks P and Eaves CJ: Cancer stem cells: An evolving concept. Nat Rev Cancer. 12:133–143. 2012.PubMed/NCBI | |
Shackleton M: Normal stem cells and cancer stem cells: Similar and different. Semin Cancer Biol. 20:85–92. 2010. View Article : Google Scholar : PubMed/NCBI | |
Sengupta A and Cancelas JA: Cancer stem cells: A stride towards cancer cure? J Cell Physiol. 225:7–14. 2010. View Article : Google Scholar : PubMed/NCBI | |
Shiozawa Y, Nie B, Pienta KJ, Morgan TM and Taichman RS: Cancer stem cells and their role in metastasis. Pharmacol Ther. 138:285–293. 2013. View Article : Google Scholar : PubMed/NCBI | |
Borovski T, De Sousa E, Melo F, Vermeulen L and Medema JP: Cancer stem cell niche: The place to be. Cancer Res. 71:634–639. 2011. View Article : Google Scholar : PubMed/NCBI | |
Yu Z, Pestell TG, Lisanti MP and Pestell RG: Cancer stem cells. Int J Biochem Cell Biol. 44:2144–2151. 2012. View Article : Google Scholar : PubMed/NCBI | |
Clevers H: The cancer stem cell: Premises, promises and challenges. Nat Med. 17:313–319. 2011. View Article : Google Scholar : PubMed/NCBI | |
Rutella S, Bonanno G, Procoli A, Mariotti A, Corallo M, Prisco MG, Eramo A, Napoletano C, Gallo D, Perillo A, et al: Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin Cancer Res. 15:4299–4311. 2009. View Article : Google Scholar : PubMed/NCBI | |
Padhye SS, Guin S, Yao HP, Zhou YQ, Zhang R and Wang MH: Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutics. Mol Pharm. 8:2310–2319. 2011. View Article : Google Scholar : PubMed/NCBI | |
Zhang SC, Balch MW, Chan HC, Lai D, Matei JM, Schilder PS, Yan PS, Huang TH and Nephew KP: Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 68:4311–4320. 2008. View Article : Google Scholar : PubMed/NCBI | |
MurilloSauca O, Chung MK, Shin JH, Karamboulas C, Wok SK, Jung YH, Oakley R, Tysome JR, Farnebo LO, Kaplan MJ, et al: CD271 is a functional and targetable marker of tumor-initiating cells in head and neck squamous cell carcinoma. Oncotarget. 5:6854–6866. 2014. View Article : Google Scholar : PubMed/NCBI | |
Tomuleasa C, Soritau O, RusCiuca D, Pop T, Todea D, Mosteanu O, Pintea B, Foris V, Susman S, Kacsó G and Irimie A: Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma. J Gastrointestin Liver Dis. 19:61–67. 2010.PubMed/NCBI | |
Bussolati B, Bruno S, Grange C, Ferrando U and Camussi G: Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J. 22:3696–3705. 2008. View Article : Google Scholar : PubMed/NCBI | |
Boiko AD, Razorenova OV, Van de Rijn M, Swetter SM, Johnson DL, Ly DP, Butler PD, Yang GP, Joshua B, Kaplan MJ, et al: Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature. 466:133–137. 2010. View Article : Google Scholar : PubMed/NCBI | |
Imai T, Tamai K, Oizumi S, Oyama K, Yamaguchi K, Sato I, Satoh K, Matsuura K, Saijo S, Sugamura K and Tanaka N: CD271 defines a stem cell-like population in hypopharyngeal cancer. PLoS One. 8:e620022013. View Article : Google Scholar : PubMed/NCBI | |
Tian J, Li X, Si M, Liu T and Li J: CD271+ osteosarcoma cells display stem-like properties. PLoS One. 9:e985492014. View Article : Google Scholar : PubMed/NCBI | |
Chen J, Song W and Amato K: Eph receptor tyrosine kinases in cancer stem cells. Cytokine Growth Factor Rev. 26:1–6. 2015. View Article : Google Scholar : PubMed/NCBI | |
Genander M and Frisén J: Ephrins and Eph receptors in stem cells and cancer. Curr Opin Cell Biol. 22:611–616. 2010. View Article : Google Scholar : PubMed/NCBI | |
Miao H, Gale NW, Guo H, Qian J, Petty A, Kaspar J, Murphy AJ, Valenzuela DM, Yancopoulos G, Hambardzumyan D, et al: EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties. Oncogene. 34:558–567. 2015. View Article : Google Scholar : PubMed/NCBI | |
Song W, Ma Y, Wang J, BrantleySieders D and Chen J: JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility and cancer stem cell-like properties in non-small cell lung cancer. Cancer Res. 74:2444–2454. 2014. View Article : Google Scholar : PubMed/NCBI | |
Sugihara E and Saya H: Complexity of cancer stem cells. Int J Cancer. 132:1249–1259. 2013. View Article : Google Scholar : PubMed/NCBI | |
Hadnagy A, Gaboury L, Beaulieu R and Balicki D: SP analysis may be used to identify cancer stem cell populations. Exp Cell Res. 312:3701–3710. 2006. View Article : Google Scholar : PubMed/NCBI | |
Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, La Noce M, Laino L, De Francesco F and Papaccio G: Cancer stem cells in solid tumors: An overview and new approaches for their isolation and characterization. FASEB J. 27:13–24. 2013. View Article : Google Scholar : PubMed/NCBI | |
Zhang Z, Liu L, GomezCasal R, Wang X, Hayashi R, Appella E, Kopelovich L and DeLeo AB: Targeting cancer stem cells with p53 modulators. Oncotarget. Apr 8–2016.(Epub ahead of print). | |
Luo Y, Nguyen N and Fujita M: Isolation of human melanoma stem cells using ALDH as a marker. Curr Protoc Stem Cell Biol. 26:Unit 3.8. 2013. View Article : Google Scholar : PubMed/NCBI | |
Chen YC, Chen YW, Hsu HS, Tseng LM, Huang PI, Lu KH, Chen DT, Tai LK, Yung MC, Chang SC, et al: Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun. 385:307–313. 2009. View Article : Google Scholar : PubMed/NCBI | |
Davies TF, Latif R, Minsky NC and Ma R: Clinical review: The emerging cell biology of thyroid stem cells. J Clin Endocrinol Metab. 96:2692–2702. 2011. View Article : Google Scholar : PubMed/NCBI | |
Klonish T, HoangVu C and Hombach-klonish S: Thyroid stem cells and cancer. Thyroid. 19:1303–1315. 2009. View Article : Google Scholar : PubMed/NCBI | |
Thomas D, Friedman S and Lin RY: Thyroid stem cells: Lessons from normal development and thyroid cancer. Endocr Relat Cancer. 15:51–58. 2008. View Article : Google Scholar : PubMed/NCBI | |
Takano T: Fetal cell carcinogenesis of the thyroid: A modified theory based on recent evidence. Endocr J. 61:311–320. 2014. View Article : Google Scholar : PubMed/NCBI | |
Takano T: Fetal cell carcinogenesis of the thyroid: Theory and practice. Semin Cancer Biol. 17:233–240. 2007. View Article : Google Scholar : PubMed/NCBI | |
Takano T and Amino N: Fetal cell carcinogenesis: A new hypothesis for better understanding of thyroid carcinoma. Thyroid. 15:432–438. 2005. View Article : Google Scholar : PubMed/NCBI | |
Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, Brooks M, Reinhardt F, Su Y and Polyak K: Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA. 108:7950–7955. 2011. View Article : Google Scholar : PubMed/NCBI | |
Lan L, Luo Y, Cui D, Shi BY, Deng W, Huo LL, Chen HL, Zhang GY and Deng LL: Epithelial-mesenchymal transition induces cancer stem cell generation in human thyroid cancer cells in vitro. Zhonghua Yi Xue Za Zhi. 93:1261–1265. 2013.(In Chinese). PubMed/NCBI | |
Hardin H, MontemayorGarcia C and Llyod RV: Thyroid cancer stem-like cells and epithelial-mesenchymal transition in thyroid cancers. Hum Pathol. 44:1707–1713. 2013. View Article : Google Scholar : PubMed/NCBI | |
Yasui K, Shimamura M, Mitsutake N and Nagayama Y: SNAIL induces epithelial-to-mesenchymal transition and cancer stem cell-like properties in aldehyde dehydroghenase-negative thyroid cancer cells. Thyroid. 23:989–996. 2013. View Article : Google Scholar : PubMed/NCBI | |
Nagayama Y, Shimamura M and Mitsutake N: Cancer stem cells in the thyroid. Front Endocrinol (Lausanne). 7:202016.PubMed/NCBI | |
Zito G, Richiusa P, Bommarito A, Carissimi E, Russo L, Coppola A, Zerilli M, Rodolico V, Criscimanna A, Amato M, et al: In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines. PloS One. 3:e35442008. View Article : Google Scholar : PubMed/NCBI | |
Friedman S, Lu M, Schultz A, Thomas D and Lin RY: CD133+ anaplastic thyroid cancer cells initiate tumors in immunodeficient mice and are regulated by thyrotropin. PLoS One. 4:e53952009. View Article : Google Scholar : PubMed/NCBI | |
Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC and Haugen BR: Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab. 93:4331–4341. 2008. View Article : Google Scholar : PubMed/NCBI | |
Todaro M, Iovino F, Eterno V, Cammareri P, Gambara G, Espina V, Gulotta G, Dieli F, Giordano S, De Maria R and Stassi G: Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res. 70:8874–8885. 2010. View Article : Google Scholar : PubMed/NCBI | |
Malaguarnera R, Morcavallo A, Giuliano S and Belfiore A: Thyroid cancer development and progression: Emerging role of cancer stem cells. Minerva Endocrinol. 37:103–115. 2012.PubMed/NCBI | |
Malaguarnera R, Frasca F, Garozzo A, Gianì F, Pandini G, Vella V, Vigneri R and Belfiore A: Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid. J Clin Endocrinol Metab. 96:766–774. 2011. View Article : Google Scholar : PubMed/NCBI | |
Li W, Reeb AN, Sewell WA, Elhomsy G and Lin RY: Phenotypic characterization of metastatic anaplastic thyroid cancer stem cells. PloS One. 8:e650952013. View Article : Google Scholar : PubMed/NCBI | |
Ahn SH, Henderson YC, Williams MD, Lai SY and Clayman GL: Detection of thyroid cancer stem cells in papillary thyroid carcinoma. J Clin Endocrinol Metab. 99:536–544. 2014. View Article : Google Scholar : PubMed/NCBI | |
Shimamura M, Nagayama Y, Matsuse M, Yamashita S and Mitsutake N: Analysis of multiple markers for cancer stem-like cells in human thyroid carcinoma cell lines. Endocr J. 61:481–490. 2014. View Article : Google Scholar : PubMed/NCBI | |
HombachKlonisch S, Natarajan S, Thanasupawat T, Medapati M, Pathak A, Ghavami S and Klonisch T: Mechanisms of therapeutic resistance in cancer (Stem) cells with emphasis on thyroid cancer cells. Front Endocrinol (Lausanne). 5:372014.PubMed/NCBI | |
Ke CC, Liu RS, Yang AH, Liu CS, Chi CW, Tseng LM, Tsai YF, Ho JH, Lee CH and Lee OK: CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy. Eur J Nucl Med Mol Imaging. 40:61–71. 2013. View Article : Google Scholar : PubMed/NCBI | |
Zane M, Scavo E, Catalano V, Bonanno M, Todaro M, De Maria R and Stassi G: Normal vs cancer thyroid stem cells: The road to transformation. Oncogene. 35:805–815. 2016. View Article : Google Scholar : PubMed/NCBI | |
Gao YJ, Li B, Wu XY, Cui J and Han JK: Thyroid tumor-initiating cells: Increasing evidence and opportunities for anticancer therapy (review). Oncology Rep. 31:1035–1042. 2014. | |
Bhatia P, Tsumagari K, Abd Elmageed ZY, Friedlander P, Buell JF and Kandil E: Stem cell biology in thyroid cancer: Insights for novel therapies. World J Stem Cells. 6:614–619. 2014. View Article : Google Scholar : PubMed/NCBI | |
Soltanian S and Matin MM: Cancer stem cells and cancer therapy. Tumour Biol. 32:425–440. 2011. View Article : Google Scholar : PubMed/NCBI | |
Abroun S, Saki N, Ahmadvand M, Asghari F, Salari F and Rahim F: STATs: An old story, yet mesmerizing. Cell J. 17:395–411. 2015.PubMed/NCBI | |
Spitzner M, Ebner R, Wolff HA, Ghadimi BM, Wienands J and Grade M: STAT3: A novel molecular mediator of resistance to chemoradiotherapy. Cancers (Basel). 6:1986–2011. 2014. View Article : Google Scholar : PubMed/NCBI | |
Tseng LM, Huang PI, Chen YR, Chen YC, Chou YC, Chen YW, Chang YL, Hsu HS, Lan YT, Chen KH, et al: Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells. J Pharmacol Exp Ther. 341:410–423. 2012. View Article : Google Scholar : PubMed/NCBI | |
Peters S and Adjei AA: MET: A promising anticancer therapeutic target. Nat Rev Clin Oncol. 9:314–326. 2012. View Article : Google Scholar : PubMed/NCBI | |
Sierra JR and Tsao MS: c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol. 3(Suppl): S21–S35. 2011. View Article : Google Scholar : PubMed/NCBI | |
Spitzweg C, Morris JC and Bible KC: New drugs for medullary thyroid cancer: New promises? Endocr Relat Cancer. May 16–2016.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI | |
PlazaMenacho I, Mologni L and McDonald NQ: Mechanisms of RET signaling in cancer: Current and future implications for targeted therapy. Cell Signal. 26:1743–1752. 2014. View Article : Google Scholar : PubMed/NCBI | |
Messina M and Robinson BG: Technology insight: Gene therapy and its potential role in the treatment of medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab. 3:290–301. 2007. View Article : Google Scholar : PubMed/NCBI | |
Fletcher JI, Williams RT, Henderson MJ, Norris MD and Haber M: ABC transporters as mediators of drug resistance and contributors to cancer cell biology. Drug Resist Updat. 26:1–9. 2016. View Article : Google Scholar : PubMed/NCBI | |
Zheng X, Cui D, Xu S, Brabant G and Derwahl M: Doxorubicin fails to eradicate cancer stem cells derived from anaplastic thyroid carcinoma cells: Characterization of resistant cells. Int J Oncol. 37:307–315. 2010.PubMed/NCBI | |
Fulawka L, Donizy P and Halon A: Cancer stem cells - the current status of an old concept: Literature review and clinical approaches. Biol Res. 47:662014. View Article : Google Scholar : PubMed/NCBI | |
Zhao Y, Bao Q, Renner A, Camaj P, Eichhorn M, Ischenko I, Angele M, Kleespies A, Jauch KW and Bruns C: Cancer stem cells and angiogenesis. Int J Dev Biol. 55:477–482. 2011. View Article : Google Scholar : PubMed/NCBI | |
Yi SY, Hao YB, Nan KJ and Fan TL: Cancer stem cells niche: A target for novel cancer therapeutics. Cancer Treat Rev. 39:290–296. 2013. View Article : Google Scholar : PubMed/NCBI | |
Raza U, Zhang JD and Sahin O: MicroRNAs: Master regulators of drug resistance, stemness and metastasis. J Mol Med (Berl). 92:321–336. 2014. View Article : Google Scholar : PubMed/NCBI | |
Hatfield S and Ruohola-Baker H: microRNA and stem cell function. Cell Tissue Res. 331:57–66. 2008. View Article : Google Scholar : PubMed/NCBI | |
He L, Thomson JM, Hemann MT, HernandoMonge E, Mu D, Goodson S, Powers S, CordonCardo C, Lowe SW, Hannon GJ and Hammond SM: A microRNA polycistron as a potential human oncogene. Nature. 435:828–833. 2005. View Article : Google Scholar : PubMed/NCBI | |
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al: Frequent deletions and downregulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 99:15524–15529. 2002. View Article : Google Scholar : PubMed/NCBI | |
Vriens MR, Weng J, Suh I, Huynh N, Guerrero MA, Shen WT, Duh QY, Clark OH and Kebebew E: MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer. Cancer. 118:3426–3432. 2012. View Article : Google Scholar : PubMed/NCBI | |
Forte S, LaRosa C, Pecce V, Rosignolo F and Memeo L: The role of microRNA in thyroid carcinomas. Anticancer Res. 35:2037–2047. 2015.PubMed/NCBI | |
Zhang X, Mao H and LV Z: MicroRNA role in thyroid cancer pathogenesis. Front Biosci (Landmark Ed). 18:734–739. 2013. View Article : Google Scholar : PubMed/NCBI | |
Zhang J, Yang Y, Liu Y, Fan Y, Liu Z, Wang X, Yuan Q, Yin Y, Yu J, Zhu M, et al: MicroRNA-21 regulates biological behaviors in papillary thyroid carcinoma by targeting programmed cell death 4. J Surg Res. 189:68–74. 2014. View Article : Google Scholar : PubMed/NCBI | |
Lin X, Guan H, Li H, Liu L, Liu J, Wei G, Huang Z, Liao Z and Li Y: miR-101 inhibits cell proliferation by targeting Rac1 in papillary thyroid carcinoma. Biomed Rep. 2:122–126. 2014.PubMed/NCBI | |
Minna E, Romeo P, De Cecco L, Dugo M, Cassinelli G, Pilotti S, Degl'Innocenti D, Lanzi C, Casalini P and Pierotti MA: miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma. Oncotarget. 5:2513–2528. 2014. View Article : Google Scholar : PubMed/NCBI | |
Lv M, Zhang X, Li M, Chen Q, Ye M, Liang W, Ding L, Cai H, Fu D and Lv Z: miR-26a and its target CKS2 modulate cell growth and tumorigenesis of papillary thyroid carcinoma. PloS One. 8:e675912013. View Article : Google Scholar : PubMed/NCBI | |
Liu X, He M, Hou Y, Liang B, Zhao L, Ma S, Yu Y and Liu X: Expression profiles of microRNAs and their target genes in papillary thyroid carcinoma. Oncol Rep. 4:1415–1420. 2013. | |
Zhang X, Li M, Zuo K, Li D, Ye M, Ding L, Cai H, Fu D, Fan Y and Lv Z: Upregulated miR-155 in papillary thyroid carcinoma promotes tumor growth by targeting APC and activating Wnt/β-catenin signaling. J Clin Endocrinol Metab. 98:E1305–E1313. 2013. View Article : Google Scholar : PubMed/NCBI | |
Wang Z, Zhang H, Zhang P, Li J, Shan Z and Teng W: Upregulation of miR-2861 and miR-451 expression in papillary thyroid carcinoma with lymph node metastasis. Med Oncol. 30:5772013. View Article : Google Scholar : PubMed/NCBI | |
Chou CK, Yang KD, Chou FF, Huang CC, Lan YW, Lee YF, Kang HY and Liu RT: Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma. J Clin Endocrinol Metab. 98:E196–E205. 2013. View Article : Google Scholar : PubMed/NCBI | |
Zhang J, Liu Y, Liu Z, Wang XM, Yin DT, Zheng LL, Zhang DY and Lu XB: Differential expression profiling and functional analysis of microRNAs through stage I–III papillary thyroid carcinoma. Int J Med Sci. 10:585–592. 2013. View Article : Google Scholar : PubMed/NCBI | |
Pallante P, Visone R, Ferracin M, Ferraro A, Berlingieri MT, Troncone G, Chiappetta G, Liu CG, Santoro M, Negrini M, et al: MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer. 13:497–508. 2006. View Article : Google Scholar : PubMed/NCBI | |
Stokowy T, Eszlinger M, Świerniak M, Fujarewicz K, Jarząb B, Paschke R and Krohn K: Analysis options for high-throughput sequencing in miRNA expression profiling. BMC Res Notes. 7:1442014. View Article : Google Scholar : PubMed/NCBI | |
Jikuzono T, Kawamoto M, Yoshitake H, Kikuchi K, Akasu H, Ishikawa H, Hirokawa M, Miyauchi A, Tsuchiya S, Shimizu K and Takizawa T: The miR-221/222 cluster, miR-10b and miR-92a are highly upregulated in metastatic minimally invasive follicular thyroid carcinoma. Int J Oncol. 42:1858–1868. 2013.PubMed/NCBI | |
Rossing M, Borup R, Henao R, Winther O, Vikesaa J, Niazi O, Godballe C, Krogdahl A, Glud M, Hjort-Sørensen C, et al: Down-regulation of microRNAs controlling tumourigenic factors in follicular thyroid carcinoma. J Mol Endocrinol. 48:11–23. 2012. View Article : Google Scholar : PubMed/NCBI | |
Puppin C, Durante C, Sponziello M, Verrienti A, Pecce V, Lavarone E, Baldan F, Campese AF, Boichard A, Lacroix L, et al: Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation. Endocrine. 47:528–536. 2014. View Article : Google Scholar : PubMed/NCBI | |
Hudson J, Duncavage E, Tamburrino A, Salerno P, Xi L, Raffeld M, Moley J and Chernock RD: Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma. Exp Mol Pathol. 95:62–67. 2013. View Article : Google Scholar : PubMed/NCBI | |
Reddi HV, Driscoll CB, Madde P, Milosevic D, Hurley RM, McDonough SJ, HallangerJohnson J, McIver B and Eberhardt NL: Redifferentiation and induction of tumor suppressors miR-122 and miR-375 by the PAX8/PPARγ fusion protein inhibits anaplastic thyroid cancer: A novel therapeutic strategy. Cancer Gene Ther. 20:267–275. 2013. View Article : Google Scholar : PubMed/NCBI | |
Zhang Z, Liu ZB, Ren WM, Ye XG and Zhang YY: The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells. Int J Mol Med. 30:856–862. 2012.PubMed/NCBI | |
Takakura S, Mitsutake N, Nakashima M, Namba H, Saenko VA, Rogounovitch TI, Nakazawa Y, Hayashi T, Ohtsuru A and Yamashita S: Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Sci. 99:1147–1154. 2008. View Article : Google Scholar : PubMed/NCBI | |
Yu S, Liu Y, Wang J, Guo Z, Zhang Q, Yu F, Zhang Y, Huang K, Li Y, Song E, et al: Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 97:2084–2092. 2012. View Article : Google Scholar : PubMed/NCBI | |
Lee JC, Zhao JT, CliftonBligh RJ, Gill A, Gundara JS, Ip JC, Glover A, Sywak MS, Delbridge LW, Robinson BG and Sidhu SB: MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer. Cancer. 119:4358–4365. 2013. View Article : Google Scholar : PubMed/NCBI | |
Takahashi RU, Miyazaki H and Ochiya T: The role of microRNAs in the regulation of cancer stem cells. Front Genet. 4:2952014. View Article : Google Scholar : PubMed/NCBI | |
Hao J, Zhao S, Zhang Y, Zhao Z, Ye R, Wen J and Li J: Emerging role of microRNAs in cancer and cancer stem cells. J Cell Biochem. 115:605–610. 2014. View Article : Google Scholar : PubMed/NCBI | |
Vira D, Basak SK, Veena MS, Wang MB, Batra RK and Srivatsan ES: Cancer stem cells, microRNAs, and therapeutic strategies including natural products. Cancer Metastasis Rev. 31:733–751. 2012. View Article : Google Scholar : PubMed/NCBI | |
Garg M: MicroRNAs, stem cells and cancer stem cells. World J Stem Cells. 4:62–70. 2012. View Article : Google Scholar : PubMed/NCBI | |
Hao J, Zhang Y, Deng M, Ye R, Zhao S, Wang Y, Li J and Zhao Z: MicroRNA control of epithelial-mesenchymal transition in cancer stem cells. Int J Cancer. 135:1019–1027. 2014. View Article : Google Scholar : PubMed/NCBI | |
Eramo A, Haas TL and De Maria R: Lung cancer stem cells: Tools and targets to fight lung cancer. Oncogene. 29:4625–4635. 2010. View Article : Google Scholar : PubMed/NCBI |